Cytokinetics Stock News

If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlyin

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

Cytokinetics: CEO Talks Down Buyout Prospects

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere

Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4

The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to

Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS).  Shares of the biopharmaceutical company hav

Novartis has backed away from its pursuit of Cytokinetics.

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.